Cargando…

Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring

AIMS/INTRODUCTION: To assess the effects of sodium glucose co-transporter 2 inhibitor therapy on the pathophysiology of type 2 diabetes. MATERIALS AND METHODS: We administered ipragliflozin to 21 inpatients with type 2 diabetes for 7 days, and analyzed the diurnal profiles of plasma glucose and 3-hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Kentaro, Nakayama, Hitomi, Yoshinobu, Satoko, Kawano, Seiko, Tsuruta, Munehisa, Nohara, Masayuki, Hasuo, Rika, Akasu, Shoko, Tokubuchi, Ichiro, Wada, Nobuhiko, Hirao, Saori, Iwata, Shinpei, Kaku, Hiroo, Tajiri, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627548/ https://www.ncbi.nlm.nih.gov/pubmed/26543545 http://dx.doi.org/10.1111/jdi.12370

Ejemplares similares

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes
por: Tajiri, Yuji, et al.
Publicado: (2014)

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
por: Kutoh, Eiji, et al.
Publicado: (2016)

Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
por: Ueno, Hiroaki, et al.
Publicado: (2018)

Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study
por: Okada, Junichi, et al.
Publicado: (2020)

Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy
por: Eguchi, Hiroyuki, et al.
Publicado: (2015)

CD36 regulates diurnal glucose metabolism and hepatic clock to maintain glucose homeostasis in mice
por: Chen, Mengyue, et al.
Publicado: (2023)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
por: Choi, Min-Koo, et al.
Publicado: (2020)

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
por: Nagayama, Ayako, et al.
Publicado: (2019)

Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
por: Izumi, Keita, et al.
Publicado: (2019)

Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring
por: Kawaguchi, Yuji, et al.
Publicado: (2020)

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
por: Saito, Masako, et al.
Publicado: (2020)

Diurnal Regulation of Peripheral Glucose Metabolism: Potential Effects of Exercise Timing
por: Mancilla, Rodrigo, et al.
Publicado: (2020)

Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis
por: Iuchi, Hiroyuki, et al.
Publicado: (2017)

Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome
por: Nagashima, Shuichi, et al.
Publicado: (2020)

The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
por: Okura, Tsuyoshi, et al.
Publicado: (2022)

Determination of physiological parameters for endogenous glucose production in individuals using diurnal data
por: van Stee, Mariël F., et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
por: Saito, Masako, et al.
Publicado: (2019)

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy
por: Nagai, Yoshio, et al.
Publicado: (2019)

Surrogate index for insulin sensitivity composed of factors not using glucose and insulin in Japanese patients with diabetes
por: Tajiri, Yuji, et al.
Publicado: (2011)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3
por: Gobaru, Mizuki, et al.
Publicado: (2019)

Diurnal and other variations in blood glucose in intensive care unit patients receiving insulin infusions
por: Smith, S, et al.
Publicado: (2007)

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
por: Shikata, Masato, et al.
Publicado: (2020)

Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats
por: Tokubuchi, Ichiro, et al.
Publicado: (2017)

The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
por: Takeda, Akihiko, et al.
Publicado: (2017)

Evaluation of newly developed veterinary portable blood glucose meter with hematocrit correction in dogs and cats
por: MORI, Akihiro, et al.
Publicado: (2017)

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
por: Tobe, Kazuyuki, et al.
Publicado: (2017)

Subcutaneous glucose measurements and glucose regulation (?)
por: Ligtenberg, Jack J., et al.
Publicado: (2010)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation
por: Fukudo, Shin, et al.
Publicado: (2019)

A diurnal rhythm in glucose uptake in brown adipose tissue revealed by in vivo PET-FDG imaging
por: van der Veen, Daan R, et al.
Publicado: (2012)

Diurnal variability of glucose tetrasaccharide (Glc(4)) excretion in patients with glycogen storage disease type III
por: Young, Sarah P., et al.
Publicado: (2020)

The Association of Diurnal Blood Glucose Variability With Subclinical Cardiac Disease in Patients With Type 2 Diabetes Mellitus
por: Shehab-Eldin, Walid, et al.
Publicado: (2020)

Diurnal in vivo xylem sap glucose and sucrose monitoring using implantable organic electrochemical transistor sensors
por: Diacci, Chiara, et al.
Publicado: (2020)

Gastric bypass alters diurnal feeding behavior and reprograms the hepatic clock to regulate endogenous glucose flux
por: Ye, Yuanchao, et al.
Publicado: (2023)

Low dose of sodium-glucose transporter 2 inhibitor ipragliflozin attenuated renal dysfunction and interstitial fibrosis in adenine-induced chronic kidney disease in mice without diabetes
por: Yamato, Mayumi, et al.
Publicado: (2020)

The effects of postprandial glucose and insulin levels on postprandial endothelial function in subjects with normal glucose tolerance
por: Suzuki, Kazunari, et al.
Publicado: (2012)

Initial distribution volume of glucose can be approximated using a conventional glucose analyzer in the intensive care unit
por: Ishihara, Hironori, et al.
Publicado: (2005)

Glucose
Publicado: (1881)

Cannot write session to /tmp/vufind_sessions/sess_lodadkoo2a8u751j70sseuhpl2